Tech Company Financing Transactions
Tevogen Bio Funding Round
Tevogen Bio, operating out of Warren, secured $1 million in investment from KRHP.
Transaction Overview
Company Name
Announced On
8/2/2025
Transaction Type
Debt
Amount
$1,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This grant is an endorsement of its potential role in accelerating drug development, bringing down costs, speeding up timelines, and expanding access to precision cell therapies for those who need them most.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Warren, NJ Undisclosed
USA
Warren, NJ Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ryan Saadi
Browse more venture capital transactions:
Prev: 8/1/2025: Merso venture capital transaction
Next: 8/3/2025: BioConsortia venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs